ACHP Recommendations to Strengthen CMS Drug Price Negotiation Guidance for 2028
ACHP strongly supports the inclusion of Medicare Part B drugs and the renegotiation of previously selected drugs from 2026 and 2027.
Tag: outcome-based drug contracts
Investing in the Right Care at the Right Time
ACHP member companies are focused on delivering the right care at the right time, leading to better outcomes and higher value care.
Point32 Trailblazes with Value-based Drug Contracts (STAT News)
Point32 Health continues to trailblaze drug price negotiation with a new value-based contract for lung cancer treatment.
